AKEBIA THERAPEUTICS, INC. Payments to Acquire Available-for-sale Securities
AKEBIA THERAPEUTICS, INC. (AKBA) reported Payments to Acquire Available-for-sale Securities of $172.44 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-11-08
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $50.97M, a 42.15% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $72.87M, a 19.12% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $48.60M, a 58.24% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $64.99M, a 337.01% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $330.64M, a 124.91% increase from fiscal 2016.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $147.01M, a 90.49% increase from fiscal 2015.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2015 was $77.17M, a 0.69% decline from fiscal 2014.
- AKEBIA THERAPEUTICS, INC. payments to acquire available-for-sale securities for fiscal 2014 was $77.71M, a 480.08% increase from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|
| 2018-09-30 | $50.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $123.84M derived: sum of 2 quarters · filed 2018-11-08 | $172.44M 10-Q · filed 2018-11-08 | $237.43M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2018-06-30 | $72.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $121.47M 10-Q · filed 2018-08-08 | $186.45M derived: sum of 3 quarters · filed 2018-08-08 | $274.57M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2018-03-31 | $48.60M 10-Q · filed 2018-05-09 | $113.59M derived: sum of 2 quarters · filed 2018-05-09 | $201.70M derived: sum of 3 quarters · filed 2018-11-08 | $262.87M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-12-31 | $64.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $153.10M derived: sum of 2 quarters · filed 2018-11-08 | $214.27M derived: sum of 3 quarters · filed 2018-11-08 | $330.64M 10-K · filed 2018-03-12 | |
| 2017-09-30 | $88.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $149.28M derived: sum of 2 quarters · filed 2018-11-08 | $265.65M 10-Q · filed 2018-11-08 | $280.52M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-06-30 | $61.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $177.54M 10-Q · filed 2018-08-08 | $192.41M derived: sum of 3 quarters · filed 2018-08-08 | $205.86M derived: sum of 4 quarters · filed 2018-08-08 | |
| 2017-03-31 | $116.37M 10-Q · filed 2018-05-09 | $131.24M derived: sum of 2 quarters · filed 2018-05-09 | $144.69M derived: sum of 3 quarters · filed 2018-05-09 | $163.22M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2016-12-31 | $14.87M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $28.32M derived: sum of 2 quarters · filed 2018-03-12 | $46.85M derived: sum of 3 quarters · filed 2018-03-12 | $147.01M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $13.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $31.98M derived: sum of 2 quarters · filed 2017-11-08 | $132.14M 10-Q · filed 2017-11-08 | $144.78M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-06-30 | $18.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $118.68M 10-Q · filed 2017-08-08 | $131.33M derived: sum of 3 quarters · filed 2018-03-12 | $160.43M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-03-31 | $100.16M 10-Q · filed 2017-05-09 | $112.80M derived: sum of 2 quarters · filed 2018-03-12 | $141.90M derived: sum of 3 quarters · filed 2018-03-12 | $171.35M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2015-12-31 | $12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $41.74M derived: sum of 2 quarters · filed 2018-03-12 | $71.19M derived: sum of 3 quarters · filed 2018-03-12 | $77.17M 10-K · filed 2018-03-12 | |
| 2015-09-30 | $29.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $58.55M derived: sum of 2 quarters · filed 2016-11-09 | $64.53M 10-Q · filed 2016-11-09 | $77.74M derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-06-30 | $29.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $35.43M 10-Q · filed 2016-08-08 | $48.65M derived: sum of 3 quarters · filed 2017-03-06 | $88.85M derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-03-31 | $5.98M 10-Q · filed 2016-05-05 | $19.19M derived: sum of 2 quarters · filed 2017-03-06 | $59.40M derived: sum of 3 quarters · filed 2017-03-06 | ||
| 2014-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $53.42M derived: sum of 2 quarters · filed 2017-03-06 | $77.71M 10-K · filed 2017-03-06 | ||
| 2014-09-30 | $40.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $64.50M 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | $24.29M 10-Q · filed 2015-08-11 | ||||
| 2013-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $13.40M 10-K · filed 2016-03-14 | $13.39M 10-K · filed 2015-03-04 | ||
| 2013-09-30 | $13.15M 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |